Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

Asahi Kasei rides renal momentum with $1.1B Calliditas takeout

Deal gives Japanese pharma Tarpeyo, first drug approved to treat IgA nephropathy 

By Lauren Martz, Executive Director, Biopharma Intelligence
May 28, 2024 10:10 PM UTC

In the fourth $1 billion-plus pharma deal for a renal disease asset in the past 12 months, Asahi Kasei is gaining the first drug approved to treat IgA nephropathy via its acquisition of Calliditas.

Asahi Kasei Corp. (Tokyo:3407) will acquire the biotech for SEK208 ($19.69) per share, for a total deal value of SEK11,164 ($1.1 billion). The price represents an 83% premium over Monday’s close of SEK113.60...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Asahi Kasei Corp.

Biogen Inc.

Calliditas Therapeutics AB

Novartis AG

Vertex Pharmaceuticals Inc.